Biomarkers for the lung cancer diagnosis and their advances in proteomics
Authors:
- Je-Yoel ChoJCJe-Yoel Cho
Open Access
- 30 September 2008
- journal article
- review article
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 41 (9) , 615-625
Abstract
Biomarkers for the lung cancer diagnosis and their advances in proteomics Biomarkers;Diagnosis;Lung cancer;Proteomics;Serum/plasma; Over a last decade, intense interest has been focused on biomarker discovery and their clinical uses. This interest is accelerated by the completion of human genome project and the progress of techniques in proteomics. Especially, cancer biomarker discovery is eminent in this field due to its anticipated critical role in early diagnosis, therapy guidance, and prognosis monitoring of cancers. Among cancers, lung cancer, one of the top three major cancers, is the one showing the highest mortality because of failure in early diagnosis. Numerous potential DNA biomarkers such as hypermethylations of the promoters and mutations in K-ras, p53, and protein biomarkers; carcinoembryonic antigen (CEA), CYFRA21-1, plasma kallikrein B1 (KLKB1), Neuron-specific enolase, etc. have been discovered as lung cancer biomarkers. Despite extensive studies thus far, few are turned out to be useful in clinic. Even those used in clinic do not show enough sensitivity, specificity and reproducibility for general use. This review describes what the cancer biomarkers are for, various types of lung cancer biomarkers discovered at present and predicted future advance in lung cancer biomarker discovery with proteomics technology.Keywords
This publication has 74 references indexed in Scilit:
- Proteomic Profiling of Endothelial Cells in Human Lung CancerJournal of Proteome Research, 2008
- Cancer Biomarkers—An Invitation to the TableScience, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Lung Cancer ScreeningNew England Journal of Medicine, 2005
- An Overview of Lung Cancer Genomics and ProteomicsAmerican Journal of Respiratory Cell and Molecular Biology, 2005
- What is the role of radiotherapy in bladder-preserving cancer therapy?Nature Clinical Practice Oncology, 2005
- Gene-promoter hypermethylation as a biomarker in lung cancerNature Reviews Cancer, 2004
- Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapyNature, 2004
- Imatinib mesylate in the treatment of chronic myeloid leukaemiaExpert Opinion on Pharmacotherapy, 2003
- Use of rituximab, the new FDA-approved antibodyCurrent Opinion in Oncology, 1998